NCT03156595UnknownNot Applicable
Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies
University Hospital, Strasbourg, France2 sites in 1 country108 target enrollmentStarted: August 4, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 108
- Locations
- 2
- Primary Endpoint
- Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the sensitive dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.
Study Overview
Brief Summary
Chimiotherapy produces neuropathies injuries to 30% to 70% cases. A third of those patients keeps suffering from this side effects disabilities and their quality of life is seriously affected.
Hypnosis, as a non-invasive tool without physical side effects, might be used to relieve them.
the purpose of this trial based on our own experience, is to demonstrate the value of using hypnosis and self-hypnosis in chimiotherapy- induced chronic neuropathies.
The aim will be to sustainably improve the quality of life by expanding self-management of pain and motor function side effect.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Minimum age :18 years
- •Chemiotherapy- induced chronic neuropathies for at least 2 months with a DN4 score >4
- •Failure of classic treatment used to relief neuropathic
- •Having stopped chemotherapy treatment and being in complete or partial response or in tumoral stability
- •Without any planed chemiotherapy during the study
- •Having signed a written informed consent.
- •French efficient understanding
- •With health insurance coverage
- •availability during all the study
- •With efficient contraception for women of childbearing age
Exclusion Criteria
- •No participation to another study at the same time
- •Suffering from neuropathy before having chemotherapy
- •Other disease that may cause neuropathy
- •Any medicine that could cause neuropathy
- •Neurological or psychiatrical disease past or present
- •Mental retardation
- •Allergy to EMG's electrodes
- •Unable to consent, under tutelage or curatorship or judiciary safeguard
- •Pregnant or nursing woman
Outcomes
Primary Outcomes
Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the sensitive dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.
Time Frame: Day 84
Secondary Outcomes
- Measure benefits of hypnosis on a psychotropic treatments(Day 0, Day 28, day 56 and Day 84.)
- Measure benefits of hypnosis on electrophysiological abnormalities related to neuropathy(Day 84)
- Measure benefits of hypnosis on tendon reflexes, deep and superficial sensitivity, muscular strength(Day 84)
- Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the motor dimension of the quality of life of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.(Day 84)
- Measure at 12 weeks (D84) benefits of hypnosis and self-hypnosis on the loss of autonomy of patients with chronic peripheral neuropathies arising from a cancer chemotherapy and inadequately relief with reference treatments.(Day 84)
- Measure benefits of hypnosis on self- hypnosis in the experimental group(Day 28, Day 56 and D84)
- Evaluate the safety in the two arms, due to hypnosis adverse effects, to pain treatment or another reason(Day 0, Day 28, Day 56, Day 84 and in case of serious adverse event)
- Measure benefits of hypnosis on the neuropathic pain intensity(Day 28, day 56 and Day 84.)
- Measure benefits of hypnosis on analgesic treatments(Day 0, Day 28, day 56 and Day 84.)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
COMT Activity and HypnotizabilityPain, PostoperativeGenetic PredispositionNCT04624880Stanford University80
Completed
Not Applicable
Autohypnosis and CancerologyBreast CancerColorectal CancerNCT03429296Groupe Hospitalier Mutualiste de Grenoble120
Completed
Not Applicable
Home-based Non-invasive Brain Stimulation for Treatment-resistant Depression Feasibility, Efficacy and Biomarker of Treatment ResponseMajor Depressive DisorderNCT05930509Institut Guttmann40
Completed
Not Applicable
Impact of Hypnosis During Invasive Procedure in Intensive Care UnitPainNCT04399850Assistance Publique - Hôpitaux de Paris124
Completed
Not Applicable
The Efficacy of Hypnotic Cognitive Therapy for Chronic Pain in SCISpinal Cord InjuriesChronic PainNCT03857672University of Washington129